Bassel Rifai - Ambu AS Chief VP
| AMBFF Stock | USD 19.90 0.10 0.50% |
Insider
Bassel Rifai is Chief VP of Ambu AS
| Phone | 45 72 25 20 00 |
| Web | https://www.ambu.com |
Ambu AS Management Efficiency
The company has return on total asset (ROA) of 0.0141 % which means that it generated a profit of $0.0141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0236 %, meaning that it generated $0.0236 on every $100 dollars invested by stockholders. Ambu AS's management efficiency ratios could be used to measure how well Ambu AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ashley Cordova | Novocure | 45 | |
| Richard Holifield | Globus Medical | N/A | |
| Lauren Budden | Insulet | 49 | |
| Uri MD | Novocure | 45 | |
| Julie Dewey | Nevro Corp | 63 | |
| Kelly Huller | Globus Medical | 48 | |
| Steven Payne | Globus Medical | 53 | |
| Stephen Zarrilli | Globus Medical | 58 | |
| Sridhar Kosaraju | Nevro Corp | 42 | |
| Ajit Ramalingam | Bio Rad Laboratories | 51 | |
| Robert Douglas | Globus Medical | 60 | |
| Karen Prange | Nevro Corp | 56 | |
| Mike Reeder | Globus Medical | N/A | |
| Richard Carter | Nevro Corp | 53 | |
| Michael Carter | Nevro Corp | 52 | |
| Ingrid Goldberg | Novocure | N/A | |
| Simon May | Bio Rad Laboratories | 52 | |
| John Dowling | Globus Medical | N/A | |
| Pr MD | Novocure | 86 | |
| Donald Middlebrook | Nevro Corp | 69 | |
| William Burke | Novocure | 69 | |
Management Performance
| Return On Equity | 0.0236 | |||
| Return On Asset | 0.0141 |
Ambu AS Leadership Team
Elected by the shareholders, the Ambu AS's board of directors comprises two types of representatives: Ambu AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ambu. The board's role is to monitor Ambu AS's management team and ensure that shareholders' interests are well served. Ambu AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ambu AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Schmidt, Ex CFO | ||
| Henrik Ankjr, Ex Operations | ||
| Thomas Henriksen, Director, Employee Representative | ||
| Anders Williamsson, Managing Director | ||
| Steven Block, CEO USA | ||
| Nicolai Thomsen, Director Planning | ||
| Mikkel Wagner, Director Communications | ||
| Bassel Rifai, Chief VP | ||
| Mns Barsne, Ex Officer | ||
| Britt Jensen, Chief Officer |
Ambu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ambu AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0236 | |||
| Return On Asset | 0.0141 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 3.73 B | |||
| Shares Outstanding | 219.75 M | |||
| Shares Owned By Insiders | 26.04 % | |||
| Shares Owned By Institutions | 36.20 % | |||
| Price To Earning | 64.15 X | |||
| Price To Book | 5.10 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ambu Pink Sheet
Ambu AS financial ratios help investors to determine whether Ambu Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ambu with respect to the benefits of owning Ambu AS security.